Risedronic acid

Generic Name: Risedronic acid

Brand Names: Actonel, Atelvia

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₁NO_₇P_₂

CAS Number: 105462-24-6

Unique Ingredient Identifier: KM2Z91756Z

Background: Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Indication: Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.

Associated Conditions: Hypercalcemia of Malignancy, Osteoporosis, Paget’s Disease

Associated Therapies: -

Clinical Trials

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Phase 3

Completed

Conditions: Breast Cancer
Osteoporosis

First Posted Date: 2006-07-20

Last Posted Date: 2020-04-02

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 497

Registration Number: NCT00354302

Locations: 🇨🇦
Cambridge Memorial Hospital, Cambridge, Ontario, Canada
🇨🇦
Odette Cancer Centre, Toronto, Ontario, Canada
🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada

and more 10 locations

Risedronate in Postmenopausal Women With Low Bone Density

Phase 2

Completed

Conditions: OSTEOPOROSIS, POSTMENOPAUSAL

First Posted Date: 2006-07-12

Last Posted Date: 2012-02-17

Lead Sponsor: Sanofi

Target Recruit Count: 150

Registration Number: NCT00351091

Risedronate in Osteopenic Postmenopausal Women

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: risedronate
Drug: risedronate placebo

First Posted Date: 2006-06-28

Last Posted Date: 2009-12-07

Lead Sponsor: Sanofi

Target Recruit Count: 156

Registration Number: NCT00345644

Locations: 🇫🇷
Sanofi-Aventis, Paris, France

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

Phase 3

Completed

Conditions: Back Pain
Spinal Fracture
Osteoporosis, Postmenopausal

Interventions: Drug: teriparatide
Drug: risedronate
Drug: placebo

First Posted Date: 2006-06-22

Last Posted Date: 2011-05-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 712

Registration Number: NCT00343252

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden

Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS

Phase 3

Withdrawn

Conditions: Breast Cancer
Osteoporosis

First Posted Date: 2006-05-11

Last Posted Date: 2012-11-29

Lead Sponsor: ETOP IBCSG Partners Foundation

Registration Number: NCT00324714

Locations: 🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Oncocare Sonnenhof-Klinik Engeriedspital, Bern, Switzerland

IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)

Phase 3

Completed

Conditions: Osteoporosis

First Posted Date: 2005-12-22

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Registration Number: NCT00268632

Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.

Phase 1

Completed

Conditions: Renal Transplant Osteodystrophy

Interventions: Drug: Placebo
Drug: Risedronate

First Posted Date: 2005-12-19

Last Posted Date: 2019-03-01

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 60

Registration Number: NCT00266708

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

A Study of Monthly Risedronate for Osteoporosis

Phase 3

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: risedronate

First Posted Date: 2005-11-01

Last Posted Date: 2013-04-22

Lead Sponsor: Warner Chilcott

Target Recruit Count: 1294

Registration Number: NCT00247273

Locations: 🇪🇸
Research Site, Madrid, Spain

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Phase 3

Terminated

Conditions: Metastatic Prostate Cancer

Interventions: Drug: Placebo
Drug: Risedronate

First Posted Date: 2005-09-22

Last Posted Date: 2016-05-26

Lead Sponsor: Christopher Sweeney, MBBS

Target Recruit Count: 63

Registration Number: NCT00216060

Locations: 🇺🇸
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
🇺🇸
Quality Cancer Center (MCGOP), Indianapolis, Indiana, United States
🇺🇸
David Reed, M.D., Seattle, Washington, United States

and more 42 locations

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Risedronate
Drug: Parathyroid Hormone

First Posted Date: 2005-09-22

Last Posted Date: 2015-06-25

Lead Sponsor: University of California, Davis

Target Recruit Count: 60

Registration Number: NCT00221299

Locations: 🇺🇸
UC Davis General Medicine Research Clinic, Sacramento, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy